Fluvastatin Versus Hepatitis C Virus
Information source: Bader, Ted, M.D.
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Hepatitis C
Intervention: fluvastatin (Drug)
Phase: N/A
Status: Active, not recruiting
Sponsored by: Bader, Ted, M.D. Official(s) and/or principal investigator(s):
Ted Bader, MD, Principal Investigator, Affiliation: VA Medical Center and University of Oklahoma
Summary
This is a dose finding and efficacy trial for fluvastatin versus hepatitis C.
Clinical Details
Official title: A Dose Finding Study of Fluvastatin for in Vivo Demonstration of Inhibiting Hepatitis C Replication in Patients Infected With Chronic Hepatitis C
Study design: Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Primary outcome: Viral Load Reduction, Liver test changes
Detailed description:
Four different oral doses of fluvastatin will be used for 14 days and the viral load of
hepatitis C will be measured weekly. This has been extended to different doses for 9-12
weeks.
Eligibility
Minimum age: 18 Years.
Maximum age: 75 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- HCV RNA positive
Exclusion Criteria:
- Testing positive for alcohol or marijuana
Locations and Contacts
VA Medical Center, Oklahoma City, Oklahoma 73104, United States
Additional Information
Starting date: September 2006
Ending date: February 2007
Last updated: February 28, 2007
|
